What is Big Think?  

We are Big Idea Hunters…

We live in a time of information abundance, which far too many of us see as information overload. With the sum total of human knowledge, past and present, at our fingertips, we’re faced with a crisis of attention: which ideas should we engage with, and why? Big Think is an evolving roadmap to the best thinking on the planet — the ideas that can help you think flexibly and act decisively in a multivariate world.

A word about Big Ideas and Themes — The architecture of Big Think

Big ideas are lenses for envisioning the future. Every article and video on bigthink.com and on our learning platforms is based on an emerging “big idea” that is significant, widely relevant, and actionable. We’re sifting the noise for the questions and insights that have the power to change all of our lives, for decades to come. For example, reverse-engineering is a big idea in that the concept is increasingly useful across multiple disciplines, from education to nanotechnology.

Themes are the seven broad umbrellas under which we organize the hundreds of big ideas that populate Big Think. They include New World Order, Earth and Beyond, 21st Century Living, Going Mental, Extreme Biology, Power and Influence, and Inventing the Future.

Big Think Features:

12,000+ Expert Videos


Browse videos featuring experts across a wide range of disciplines, from personal health to business leadership to neuroscience.

Watch videos

World Renowned Bloggers


Big Think’s contributors offer expert analysis of the big ideas behind the news.

Go to blogs

Big Think Edge


Big Think’s Edge learning platform for career mentorship and professional development provides engaging and actionable courses delivered by the people who are shaping our future.

Find out more

An Introduction to Breakthroughs: Cancer

February 22, 2011, 12:00 AM

Everyone knows someone that has been touched by cancer. Over one and a half million Americans will be diagnosed with some form of cancer in 2011, and more than 560,000 will die from the disease, accounting for 1 out of every 5 deaths.

But with the unlocking of the human and cancer genomes, a new era of cancer research is dawning. Leading researchers believe that existing treatments, including highly toxic chemotherapy and radiation will soon be replaced with more precise, less harmful, and more successful therapies. Yet the question remains: will we ever find a universal cure?

In December, Big Think hosted a panel discussion to discuss this question and to highlight cutting-edge cancer research as part of our Breakthroughs series, made possible by Pfizer. This conversation featured back-and-forth exchanges between top luminaries in the field, including:

Dr. Harold Varmus, Director of the National Cancer Institute. Dr. Varmus won the Nobel Prize in Physiology or Medicine in 1989 for discovering the cellular origin of retroviral oncogenes.


Walsh 160

Dr. Doug Schwartzentruber, Surgical Oncologist at the Goshen Center for Cancer Care. Time magazine ranked Dr. Schwartzentruber as one of the world's 100 most influential people in 2010. 


Bookheimer 160

Dr. Deborah Schrag, Medical Oncologist at Dana-Farber Cancer Institute in Boston. Dr. Schrag is also an associate professor of medicine at Harvard Medical School.  


Bookheimer 160

Dr. Lewis Cantley, Professor of cell biology at Harvard Medical School. His discovery and study of the enzyme PI-3-kinase have proved highly influential for cancer research. 

Bookheimer 160

This panel was moderated by Dr. Siddhartha Mukherjee, Assistant Professor of Medicine at Columbia University. Dr. Mukherjee is the author of "The Emperor of All Maladies: A Biography of Cancer," which was nominated as a National Book Critics Circle Award finalist.


Over the next four weeks, Big Think will look at the latest thinking and research about the causes and progression of cancer, using information from this panel discussion to analyze new information about predisposition to the disease and what might be done to prevent it.

Produced by Big Think and made possible by Pfizer, Breakthroughs is a three-part series that focuses on leading-edge medical research. The previous two installments focused on Alzheimer's disease and autism.

The views expressed here are solely those of the participants, and do not represent the views of Big Think or its sponsors.


An Introduction to Breakthr...

Newsletter: Share: